stoxline Quote Chart Rank Option Currency Glossary
  
Aileron Therapeutics, Inc. (ALRN)
4.74  -0.26 (-5.2%)    04-19 16:00
Open: 5
High: 5.025
Volume: 85,240
  
Pre. Close: 5
Low: 4.6363
Market Cap: 80(M)
Technical analysis
2024-04-19 5:07:40 PM
Short term     
Mid term     
Targets 6-month :  7.19 1-year :  8.66
Resists First :  6.15 Second :  7.42
Pivot price 5.62
Supports First :  4.11 Second :  3.42
MAs MA(5) :  5.05 MA(20) :  5.78
MA(100) :  4.42 MA(250) :  2.72
MACD MACD :  -0.2 Signal :  0
%K %D K(14,3) :  16.5 D(3) :  16.8
RSI RSI(14): 42.1
52-week High :  7.42 Low :  1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ALRN ] has closed above bottom band by 8.8%. Bollinger Bands are 30.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.04 - 5.07 5.07 - 5.09
Low: 4.55 - 4.59 4.59 - 4.62
Close: 4.68 - 4.74 4.74 - 4.79
Company Description

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Headline News

Thu, 18 Apr 2024
Aileron Therapeutics sharestarget doubled by Ladenburg Thalmann - Investing.com India

Thu, 18 Apr 2024
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies Canada

Tue, 16 Apr 2024
Aileron Therapeutics GAAP EPS of -$1.54 misses by $1.37 - Seeking Alpha

Fri, 29 Mar 2024
Aileron Therapeutics Announces CFO Transition and Appointment - TipRanks

Tue, 12 Mar 2024
Aileron Therapeutics Announces CEO Transition - Yahoo Finance

Thu, 29 Feb 2024
Aileron Therapeutics' Shareholders Approve Major Stock Proposals - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 5 (M)
Shares Float 4 (M)
Held by Insiders 0.6 (%)
Held by Institutions 63.2 (%)
Shares Short 35 (K)
Shares Short P.Month 38 (K)
Stock Financials
EPS -2.85
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.47
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -39.8 %
Return on Equity (ttm) -76.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.59
Qtrly Earnings Growth 0 %
Operating Cash Flow -14 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -1.67
PEG Ratio -1.4
Price to Book value 1.91
Price to Sales 0
Price to Cash Flow -1.68
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android